

## Press Release

### Apogenix to Present at Three Upcoming International Conferences

**Heidelberg, Germany, April 26, 2017** – Apogenix AG, a biopharmaceutical company developing next-generation immuno-oncology therapeutics, announced today that the company will present at the 13th Annual PEGS (Protein Engineering Summit), UBS – Global Healthcare Conference and Sachs 3rd Annual Immuno-Oncology: BD&L and Investment Forum.

#### **13th Annual PEGS Boston (May 1 - 5, 2017)**

Venue: Seaport World Trade Center, Boston, MA, USA

Presentation on May 1, 11:20 AM: "Hexavalent Agonists Targeting Co-Stimulatory Receptors of the TNFR-Superfamily"

Presenter: Oliver Hill, Ph.D., Vice President, Molecular Biology

Presentation on May 4, 3:20 PM: "Targeting Co-Stimulatory TNF Receptors with Hexavalent TNF Receptor Agonists (HERA)"

Presenter: Harald Fricke, M.D., CMO

#### **UBS – Global Healthcare Conference (May 22 - 24, 2017)**

Venue: Grand Hyatt New York, NY, USA

Presentation on May 23, 3:30 PM: "Apogenix - Next Generation Immuno-Oncology Therapeutics"

Presenter: Thomas Hoeger, Ph.D., CEO

#### **Sachs 3rd Annual Immuno-Oncology: BD&L and Investment Forum (June 2, 2017)**

Venue: Hyatt Chicago Magnificent Mile, Chicago, IL, USA

Presentation on June 2, 10:20 AM: Panel "New Approaches to IO & Combination Therapies"

Presenter: Juergen Gamer, Ph.D., VP Business Development

### **About Apogenix**

Apogenix is a private company developing innovative immuno-oncology therapeutics for the treatment of cancer and other malignant diseases. The company has built a promising pipeline of immuno-oncology drug candidates that target different tumor necrosis factor superfamily (TNFSF)-dependent signaling pathways, thereby restoring the immune response against tumors. Since its inception in 2005, Apogenix has raised more than 100 million euros in financing rounds, public grants, as well as upfront and milestone payments from licensing agreements. The company is based in Heidelberg, Germany.

#### **Contact**

Thomas Hoeger, Ph.D., CEO

Apogenix AG

Phone: +49 (6221) 58 60 80

E-Mail: [contact@apogenix.com](mailto:contact@apogenix.com)

Web: [www.apogenix.com](http://www.apogenix.com)

#### **Media Contacts**

Katja Arnold, Laurie Doyle

MC Services AG

Phone: +49 (89) 210 228 0

[apogenix@mc-services.eu](mailto:apogenix@mc-services.eu)